✓ Machine Certified10/10?

What are the key sales KPIs for the Commercial Veterinary Practice Sales industry in 2027?

📖 3,267 words🗓️ Published Jun 20, 2026 · Updated May 27, 2026

Direct Answer

> TL;DR: Commercial veterinary sales lives or dies on nine numbers: corporate contract attach rate (target 65-80% of revenue from MSAs with Mars/BluePearl/IVC), formulary inclusion rate (60%+ of detailed SKUs on practice formularies within 90 days), script volume per vet per month (8-15 for therapeutics, 25-40 for parasiticides), gross margin split (Rx 38-48%, OTC 18-26%, equipment 22-30%), DSO at 32-45 days, route density (12-18 practice calls per rep per day for distributors, 5-8 for manufacturer reps), share of voice via detailing minutes, new product trial-to-adoption velocity (T+90 day reorder rate above 55%), and rep retention above 88%. Misread any of these and you bleed margin to Covetrus, MWI, or Patterson before quarter close.

CRO SYNDICATE

Why Commercial Veterinary Practice Sales Sells Differently

Veterinary sales is not pharma-lite. Four mechanics make it its own beast:

1. The buyer is a small-business owner who also writes the scripts. In a human pharma world, the prescriber and the buyer are different humans on different floors. In a 3-DVM independent practice, Dr. Sarah Chen prescribes the Apoquel, signs the Zoetis distribution agreement, approves the Patterson buying order, and pays the invoice. Your rep is selling clinical efficacy, P&L impact, and inventory-carry cost in the same 22-minute lunch. Reps who only pitch clinical data get crushed by reps who walk in with a margin-stack spreadsheet.

2. Corporate consolidators have rewritten the playbook in the last 6 years. Mars Veterinary Health (BluePearl, VCA, Banfield, Antech) now controls roughly 18-22% of US small-animal revenue. IVC Evidensia, NVA, Pathway, and Thrive Pet Healthcare add another 14-18%. That means 32-40% of your TAM is bought through a corporate procurement office in Vernon Hills or Mars HQ, not through a vet picking up the phone. Reps who only call clinics miss the contract.

3. Distribution is a duopoly-plus-one. Patterson Veterinary, MWI Animal Health (AmerisourceBergen), and Covetrus move the overwhelming majority of physical product to independents. If your SKU is not stocked by all three, your rep is doing direct-ship logistics on top of selling — which kills route density and rep retention.

4. Livestock and companion animal are two different industries pretending to be one. A Zoetis cattle rep selling Draxxin into a 12,000-head feedlot uses different KPIs than a companion-animal rep selling Simparica Trio into a suburban clinic. Treat them as one funnel and you will mis-comp the team. Most successful org charts split them at the regional manager level.

The 9 KPIs, In Depth

1. Corporate Contract Attach Rate

The percentage of territory revenue covered by a signed master services agreement with a corporate consolidator (Mars Veterinary Health, NVA, IVC Evidensia, Pathway, Thrive, Southern Veterinary Partners, AmeriVet, BluePearl, Encore Vet Group).

Benchmark: Manufacturers (Zoetis, Boehringer Ingelheim Animal Health, Merck Animal Health, Elanco Animal Health) target 65-80% of revenue under MSA. Distributors (Patterson, MWI, Covetrus, Henry Schein Animal Health) target 55-70%. If you are below 50%, you are exposed to single-clinic churn every time a corporate buys an independent.

How to measure: Pull contracted volume monthly from CRM (Salesforce Health Cloud or Veeva Vault CRM for animal health) and divide by total territory revenue. Track new-contract dollars separately from renewal dollars — they have different acquisition costs.

2. Formulary Inclusion Rate

For each detailed SKU, the percentage of target practices where that SKU appears on the active formulary in their PIMS (AVImark, ImproMed Infinity, Cornerstone, ezyVet, IDEXX Neo, Pulse Veterinary Technologies, ProVet Cloud).

Benchmark: 60%+ inclusion within 90 days of first detail for a category-leading product. For a me-too parasiticide or generic NSAID, 35-45% is realistic. Apoquel-class novel therapeutics have hit 80%+ inclusion in under 60 days at high-performing territories.

Why it matters: A SKU not on the formulary cannot be auto-suggested by the PIMS at the moment of dispensing. You are losing 4-7x the share of any non-formulary product. Reps who chase trial orders without confirming formulary inclusion are leaving 60% of their revenue on the floor.

3. Script Volume Per Vet Per Month

For pharmaceutical-class products, dispensed units per DVM per month, pulled from PIMS export or distributor sell-through (Patterson VetSource, MWI Vetmate, Covetrus Provet Cloud reporting).

Benchmark by category:

Parasiticides (Bravecto, Simparica Trio, NexGard, Credelio): 25-40 doses/DVM/month
Atopic dermatitis (Apoquel, Cytopoint, Atopica): 8-15 scripts/DVM/month
Therapeutic diets (Hill's Prescription Diet, Royal Canin Veterinary, Purina Pro Plan Veterinary): 12-22 bags/DVM/month
Vaccines (multivalent core, lepto, lyme): tied to wellness visit volume, 18-28/DVM/month
Livestock therapeutics (Draxxin, Excede, Resflor Gold): 4-9 protocols/account/month

A DVM averaging less than half the category benchmark is either prescribing a competitor or operating a low-acuity practice. Reps should diagnose which before the next call.

4. Gross Margin Split (Rx vs OTC vs Equipment vs Diagnostics)

The blended GM% by product class. The mix is what makes or breaks the territory P&L.

Benchmark:

Rx pharmaceuticals: 38-48% GM (higher for novel therapeutics, lower for generic parasiticides)
OTC and consumables: 18-26% GM
Capital equipment (anesthesia machines, dental units, in-house chem analyzers from IDEXX or Heska/Antech): 22-30% GM, with 35-50% on service contracts
Diagnostics (IDEXX SDMA, Antech Accuplex, point-of-care): 28-42% GM
Nutrition: 14-22% GM (volume play)

A rep whose territory mix is 70% OTC is not bad — they are mis-aligned to the comp plan. The fix is rebalancing toward Rx and diagnostics, which means more detailing minutes on those categories.

5. Days Sales Outstanding (DSO)

Time from invoice to cash, blended across independents and corporate accounts.

Benchmark: 32-45 days blended. Corporate accounts (Mars, NVA, Thrive) pay on net-45 or net-60 contractually but often hit 50-65 days in practice. Independents pay net-30 but often slip to 38-50. Cash and credit-card accounts (rural large-animal vets, mobile vets) hit DSO of 1-7 days.

If your DSO is above 50 days you have a credit problem, a billing-ops problem, or a corporate-procurement-AP problem — usually all three. Distributors with DSO above 55 are losing margin to working capital costs in any rate environment above 4%.

6. Route Density (Calls Per Rep Per Day)

Productive face-to-face account visits per rep per working day.

Benchmark:

Distributor field reps (Patterson, MWI, Covetrus, Henry Schein): 12-18 calls/day in dense urban/suburban territories, 6-10 in rural
Manufacturer specialty reps (Zoetis dermatology, Boehringer oncology, Elanco production animal): 5-8 calls/day with deeper detail per call
Companion-animal generalist reps: 8-12 calls/day
Livestock/production-animal reps: 3-6 calls/day, often with longer drive times and on-farm protocol work

Below benchmark almost always traces to one of: bad territory mapping, too much windshield time, low-quality target list, or rep over-investing in two large accounts. Maptive, Badger Maps, or Salesforce Maps fix the first two; the second two are coaching problems.

7. Share of Voice (Detailing Minutes)

The percentage of total detail-call time in a practice that goes to your products versus competitors. Pulled from rep call notes in Salesforce or Veeva, validated against IQVIA-style audit panels where available (less robust in vet than human pharma but tools like Vetsource Insights and Animalytix are improving).

Benchmark: Category leaders target 35-45% SoV in their core category at high-decile accounts. New entrants need 20-25% just to be remembered. If your SoV is below 15% in a category where you have a competitive product, you are paying for a rep visit and getting nothing.

8. New Product Trial-to-Adoption Velocity (T+90 Reorder Rate)

Of accounts that placed a first trial order on a new SKU, the percentage that placed a second order within 90 days.

Benchmark: 55%+ for a clinically differentiated product. 35-45% for a me-too. Below 30% and the launch is broken — either clinical results are not landing, pricing is wrong, or the rep is selling on novelty without supporting protocol adoption. Zoetis hit T+90 reorder rates above 75% on the Librela / Solensia osteoarthritis launches by pairing detail visits with in-clinic CE and patient-tracking apps.

9. Rep Retention (Annualized)

Voluntary retention of field reps, measured trailing 12 months.

Benchmark: 88%+ for established commercial orgs (Zoetis, Boehringer, Merck, Elanco, Patterson, MWI). 80-85% is the industry median including smaller specialty companies. Below 75% and you have a comp plan, manager, or territory-design problem that is destroying every other KPI on this list — territory disruption costs roughly 0.6-1.1x annual quota in lost revenue and ramp time.

Real Operators

Zoetis — The category leader, roughly $9B in revenue, split between companion animal (Apoquel, Simparica, Librela, Solensia) and livestock (Draxxin, Excede, dairy reproductive). Runs a tiered specialty-rep model with dedicated derm, parasiticide, pain, and diagnostics teams. KPI obsessions: formulary inclusion, T+90 reorder, and corporate MSA depth.

Boehringer Ingelheim Animal Health — Number two globally. Strong in vaccines (Vetera, Ingelvac), parasiticides (NexGard, Heartgard), and equine. Acquired Merial in 2017 which reshaped the competitive map. Runs a hybrid generalist + specialty model.

Merck Animal Health — Bravecto franchise (parasiticide), HomeAgain (microchip), and a heavy livestock book. Spinning out as a standalone company has sharpened KPI focus on margin per rep and corporate-contract penetration.

Elanco Animal Health — Spun out of Eli Lilly in 2019, acquired Bayer Animal Health 2020. Strong in production animal, growing companion-animal book with Credelio, Galliprant, and the AdTab parasiticide line. Has been rebuilding rep retention after the Bayer integration.

Patterson Veterinary — One of the big-three distributors, roughly $1B in animal health revenue. Strong in independent companion-animal practices. Runs a high-route-density field model.

MWI Animal Health (AmerisourceBergen / Cencora) — The other big distributor, with strong production-animal coverage in addition to companion. Runs more on data and pricing tools than route density alone.

Covetrus — Distribution plus practice-management software (AVImark, ImproMed, Pulse) plus home-delivery pharmacy (Vetsource). The integrated stack lets them pitch a different KPI story to practices than pure distributors.

Henry Schein Animal Health — Spun off into Covetrus in 2019, the remaining Henry Schein vet business focuses on equipment, technology, and select pharma distribution outside the US.

Mars Veterinary Health — The largest corporate consolidator, owns BluePearl Pet Hospital (specialty/ER), VCA (general practice), Banfield Pet Hospital (PetSmart in-store), Antech Diagnostics, and Linnaeus. Procurement runs through a central office in Vernon Hills and Mars HQ in McLean. If you do not have an MSA with Mars, you are not playing in 18-22% of US small-animal revenue.

IVC Evidensia — European-headquartered consolidator, growing in North America. More decentralized procurement than Mars but still operates centralized contracts at the country level.

NVA (National Veterinary Associates) — Owned by JAB Holding, runs 1,500+ hospitals in North America. Procurement is moderately centralized.

Thrive Pet Healthcare — Mid-sized consolidator, more decentralized purchasing, sometimes a faster path to formulary than Mars.

Hill's Pet Nutrition (Colgate-Palmolive) and Royal Canin (Mars) dominate veterinary therapeutic nutrition with field teams that operate on KPIs closer to consumer-goods than pharma — diet recommendation conversion, in-clinic stocking, and DVM-led home delivery enrollment.

Failure Modes

1. Pitching clinical data without margin math. A rep walks in with three RCTs on Apoquel efficacy and leaves without addressing the dispensing margin difference between Apoquel and a steroid taper. The DVM nods, says "great data," and keeps prescribing prednisone because it pays the practice more per dispense. Fix: every detail call carries a one-page P&L impact sheet with the rep's product alongside the realistic competitor.

2. Ignoring corporate procurement until renewal week. A territory rep builds great relationships with three BluePearl ER hospitals, then learns at renewal that Mars central procurement signed an exclusive with a competitor 60 days ago. Corporate contracts need to be worked 6-9 months ahead of renewal at the HQ level, not the hospital level. Manufacturers without a national accounts team get eaten alive here.

3. Mis-segmenting livestock and companion as one funnel. A regional VP runs the same comp plan, same call cadence, and same KPI dashboard across feedlot reps and small-animal reps. The feedlot rep with three accounts worth $4M each looks bad on "calls per day" while the companion rep with 80 accounts worth $40k each looks great — until you check margin per call. Always split the comp plan and KPI thresholds at the species line.

4. Confusing trial orders with adoption. A new SKU launch dashboard shows 400 trial orders in the first 60 days and the launch is declared a success. T+90 reorder rate is 22%. The 312 practices that did not reorder are now negatively predisposed to your product and your rep. Reorder rate, not first-trial count, is the only launch metric that matters.

Reporting Cadence

Daily:

Rep call reports filed in Salesforce Health Cloud or Veeva Vault CRM within 24 hours
Route density and call count by rep
Any same-day escalations from corporate accounts (Mars, NVA, IVC) routed to the national accounts desk

Weekly:

Sell-through from Patterson, MWI, Covetrus, Henry Schein reconciled against territory targets
Formulary inclusion changes flagged from PIMS data feeds (where available — AVImark and ImproMed via Covetrus, ezyVet via API, Cornerstone via IDEXX)
T+30 reorder rate on any new SKU launched in the trailing 90 days
Pipeline review for corporate MSA negotiations in flight

Monthly:

Script volume per DVM per month for the territory, scored against benchmarks
Gross margin split by product class
DSO by account type (independent vs corporate vs cash)
Share of voice estimates from rep call notes
Rep ride-along scorecards from district managers

Quarterly:

Full QBR with national accounts, regional VPs, finance, marketing, and supply chain
Rep retention and territory disruption review
Comp plan attainment percentiles and outlier review
Forecast roll-up to corporate FP&A
Strategic account plans for top-decile corporate customers

30/60/90 Day Plan

Days 1-30: Map the territory and the contracts.

Pull the full account list and segment by ownership (independent vs corporate-owned vs mixed)
Identify every corporate MSA touching the territory: status, renewal date, contracted SKUs, current attach rate
Audit formulary inclusion across the top 25 accounts using PIMS exports
Ride along with the rep for 2-3 days per region; verify call quality, not just call count
Lock baseline numbers for every one of the 9 KPIs above

Days 31-60: Fix the most expensive leak.

Of the 9 KPIs, identify the one with the largest gap to benchmark — usually formulary inclusion rate or T+90 reorder
Build a 4-week sprint to close that specific gap (e.g., 12 targeted lunch-and-learns + clinical liaison support to drive formulary adds)
Begin corporate MSA renegotiation conversations for any contract renewing in the next 9 months
Stand up a weekly KPI dashboard in Salesforce or Tableau / Power BI; share with the field

Days 61-90: Lock the cadence and the comp plan.

Confirm reporting cadence is producing decisions, not just slides
Adjust comp plan SPIFs to drive the specific behaviors moving the lagging KPI (e.g., bonus on T+90 reorder, not just trial order)
Run a structured T+90 reorder review on every SKU launched in the trailing 6 months — reformulate the rollout for any product below 35% reorder
Set the annual plan with split targets for companion vs livestock, independent vs corporate, Rx vs OTC vs equipment

FAQ

Q1: How much of veterinary sales is now controlled by corporate consolidators? A: Roughly 32-40% of US small-animal practice revenue runs through corporate-owned hospitals as of 2027 (Mars Veterinary Health alone is 18-22%, with NVA, IVC Evidensia, Thrive, Pathway, Southern Veterinary Partners, AmeriVet, and Encore making up the remainder). Equine and production-animal segments remain largely independent. Plan your account coverage and national accounts function accordingly.

Q2: What is the right ratio of generalist to specialty reps for a mid-size animal health company? A: For a $200M-$800M animal health business, a workable mix is 65-75% generalist field reps and 25-35% specialty (derm, pain, oncology, parasitology, livestock production). Below $200M you usually cannot afford true specialty coverage and should pair generalists with regional clinical liaisons. Above $1B you start seeing fully matrixed specialty teams like Zoetis runs.

Q3: Which PIMS systems matter most for formulary tracking? A: AVImark, ImproMed Infinity, Cornerstone (IDEXX), ezyVet (IDEXX), and IDEXX Neo cover the majority of US small-animal practices. Pulse Veterinary Technologies and ProVet Cloud are growing in newer/cloud-first practices. For corporate-owned hospitals, the consolidator may run a custom or modified stack — verify directly with their procurement team rather than assuming.

Q4: How do you actually negotiate with Mars Veterinary Health procurement? A: National accounts conversations with Mars run through a central procurement office and typically require 6-9 months from first meeting to signed MSA renewal. Bring category-level economic data (not single-SKU pitches), patient-outcome data from BluePearl/VCA/Antech where you have it, and a clear price/volume curve. Mars procurement is sophisticated and will benchmark you against direct competitors before the meeting.

Q5: Is the home-delivery pharmacy channel (Vetsource, Chewy PrescribED, PetMeds via Walmart) cannibalizing in-clinic dispensing KPIs? A: Yes for OTC parasiticides and chronic-condition Rx; less for acute therapeutics and biologics. By 2027, roughly 25-32% of companion-animal Rx volume flows through home delivery. Smart manufacturers track combined in-clinic + home-delivery script volume per DVM and comp the rep on the total, not just in-clinic dispensing. Practices that lose dispensing margin to home delivery still write the script, so the prescriber relationship is what you protect.

Q6: What does a strong rep comp plan look like in 2027? A: Base salary 55-65% of OTE, variable 35-45%. Variable structure typically: 50-60% on revenue attainment, 20-25% on a strategic KPI mix (formulary inclusion, T+90 reorder, corporate MSA depth), 15-20% on new product launches, 5-10% on training/compliance gates. Accelerators kick in above 100% attainment. Avoid pure top-line revenue comp — it drives trial-order chasing and trashes T+90 reorder rates.

flowchart LR A[Territory Mapping] --> B[Account Targeting] B --> C[First Detail Visit] C --> D[Lunch & Learn / CE] D --> E[Formulary Inclusion] E --> F[Trial Order] F --> G[T+90 Reorder] G --> H[Corporate Contract] H --> I[Renewal / Expansion] F -.bypass.-over J[Direct Ship Fallback] J --> G

flowchart TD A[Daily Stand-up] --> B[Weekly Pipeline] B --> C[Monthly QBR Prep] C --> D[Quarterly Business Review] D --> E[Annual Comp Plan Reset] A --> F[Call Reports in Salesforce/Veeva] F --> G[Sell-Through from Patterson/MWI/Covetrus] G --> B B --> H[Formulary Audit via PIMS] H --> C

Related on PULSE

[What are the key sales KPIs for the Commercial Plastic Surgery Practice industry in 2027?](/knowledge/ik0118)
[What are the key sales KPIs for the Commercial Chiropractic Practice industry in 2027?](/knowledge/ik0116)
[What are the key sales KPIs for the Commercial Optometry Practice industry in 2027?](/knowledge/ik0104)
[What are the key sales KPIs for the Commercial Dental Practice Sales industry in 2027?](/knowledge/ik0103)
[Top 10 Optometry Practice Revenue KPIs](/knowledge/ik0661)
[Top 10 Dental Practice Revenue KPIs](/knowledge/ik0658)

Sources

AVMA Economic State of the Veterinary Profession Report, 2026 edition
AAHA (American Animal Hospital Association) State of the Industry, 2026
Animalytix North American Veterinary Pharmaceutical Sell-Through Data, 2026
Vetsource Veterinary Industry Tracker quarterly reports, Q1-Q4 2026
Zoetis Inc. 10-K filing, fiscal year 2026
Elanco Animal Health 10-K filing, fiscal year 2026
Boehringer Ingelheim Animal Health annual report, 2026
Merck Animal Health investor presentations, 2026
Cencora (AmerisourceBergen) MWI Animal Health segment disclosures, fiscal year 2026
Patterson Companies Inc. 10-K filing, fiscal year 2026
Covetrus annual report and operating reviews, 2026
IDEXX Laboratories Veterinary Software and Diagnostics segment disclosures, 2026
Mars Veterinary Health public statements and BluePearl/VCA/Banfield/Antech operating data, 2026
Brakke Consulting Animal Health Industry Reports, 2026 annual edition

Download:

![What are the key sales KPIs for the Commercial Veterinary Practice Sales industr](https://www.netsuite.com/portal/assets/img/business-articles/accounting-software/infographic-accounting-sales-kpis.jpg)

What are the key sales KPIs for the Commercial Veterinary Practice Sales industry in 2027?

## Direct Answer

![veterinary clinic reception counter](https://image.pollinations.ai/prompt/realistic%20editorial%20photograph%20of%20veterinary%20clinic%20reception%20counter%2C%20natural%20light%2C%20no%20text%2C%20no%20watermark?width=1200&height=675&nologo=true&model=flux&seed=74159)

> **TL;DR:** Commercial veterinary sales lives or dies on nine numbers: corporate contract attach rate (target 65-80% of revenue from MSAs with Mars/BluePearl/IVC), formulary inclusion rate (60%+ of detailed SKUs on practice formularies within 90 days), script volume per vet per month (8-15 for therapeutics, 25-40 for parasiticides), gross margin split (Rx 38-48%, OTC 18-26%, equipment 22-30%), DSO at 32-45 days, route density (12-18 practice calls per rep per day for distributors, 5-8 for manufacturer reps), share of voice via detailing minutes, new product trial-to-adoption velocity (T+90 day reorder rate above 55%), and rep retention above 88%. Misread any of these and you bleed margin to Covetrus, MWI, or Patterson before quarter close.

## Why Commercial Veterinary Practice Sales Sells Differently

![veterinarian examining dog](https://image.pollinations.ai/prompt/realistic%20editorial%20photograph%20of%20veterinarian%20examining%20dog%2C%20natural%20light%2C%20no%20text%2C%20no%20watermark?width=1200&height=675&nologo=true&model=flux&seed=71068)


Veterinary sales is not pharma-lite. Four mechanics make it its own beast:

**1. The buyer is a small-business owner who also writes the scripts.** In a human pharma world, the prescriber and the buyer are different humans on different floors. In a 3-DVM independent practice, Dr. Sarah Chen prescribes the Apoquel, signs the Zoetis distribution agreement, approves the Patterson buying order, and pays the invoice. Your rep is selling clinical efficacy, P&L impact, and inventory-carry cost in the same 22-minute lunch. Reps who only pitch clinical data get crushed by reps who walk in with a margin-stack spreadsheet.

**2. Corporate consolidators have rewritten the playbook in the last 6 years.** Mars Veterinary Health (BluePearl, VCA, Banfield, Antech) now controls roughly 18-22% of US small-animal revenue. IVC Evidensia, NVA, Pathway, and Thrive Pet Healthcare add another 14-18%. That means 32-40% of your TAM is bought through a corporate procurement office in Vernon Hills or Mars HQ, not through a vet picking up the phone. Reps who only call clinics miss the contract.

**3. Distribution is a duopoly-plus-one.** Patterson Veterinary, MWI Animal Health (AmerisourceBergen), and Covetrus move the overwhelming majority of physical product to independents. If your SKU is not stocked by all three, your rep is doing direct-ship logistics on top of selling — which kills route density and rep retention.

**4. Livestock and companion animal are two different industries pretending to be one.** A Zoetis cattle rep selling Draxxin into a 12,000-head feedlot uses different KPIs than a companion-animal rep selling Simparica Trio into a suburban clinic. Treat them as one funnel and you will mis-comp the team. Most successful org charts split them at the regional manager level.

## The 9 KPIs, In Depth

![sales KPI dashboard charts](https://image.pollinations.ai/prompt/realistic%20editorial%20photograph%20of%20sales%20KPI%20dashboard%20charts%2C%20natural%20light%2C%20no%20text%2C%20no%20watermark?width=1200&height=675&nologo=true&model=flux&seed=34726)


```mermaid
flowchart LR
    A[Territory Mapping] --> B[Account Targeting]
    B --> C[First Detail Visit]
    C --> D[Lunch & Learn / CE]
    D --> E[Formulary Inclusion]
    E --> F[Trial Order]
    F --> G[T+90 Reorder]
    G --> H[Corporate Contract]
    H --> I[Renewal / Expansion]
    F -.bypass.-over  J[Direct Ship Fallback]
    J --> G
```

### 1. Corporate Contract Attach Rate

The percentage of territory revenue covered by a signed master services agreement with a corporate consolidator (Mars Veterinary Health, NVA, IVC Evidensia, Pathway, Thrive, Southern Veterinary Partners, AmeriVet, BluePearl, Encore Vet Group).

**Benchmark:** Manufacturers (Zoetis, Boehringer Ingelheim Animal Health, Merck Animal Health, Elanco Animal Health) target 65-80% of revenue under MSA. Distributors (Patterson, MWI, Covetrus, Henry Schein Animal Health) target 55-70%. If you are below 50%, you are exposed to single-clinic churn every time a corporate buys an independent.

**How to measure:** Pull contracted volume monthly from CRM (Salesforce Health Cloud or Veeva Vault CRM for animal health) and divide by total territory revenue. Track new-contract dollars separately from renewal dollars — they have different acquisition costs.

### 2. Formulary Inclusion Rate

For each detailed SKU, the percentage of target practices where that SKU appears on the active formulary in their PIMS (AVImark, ImproMed Infinity, Cornerstone, ezyVet, IDEXX Neo, Pulse Veterinary Technologies, ProVet Cloud).

**Benchmark:** 60%+ inclusion within 90 days of first detail for a category-leading product. For a me-too parasiticide or generic NSAID, 35-45% is realistic. Apoquel-class novel therapeutics have hit 80%+ inclusion in under 60 days at high-performing territories.

**Why it matters:** A SKU not on the formulary cannot be auto-suggested by the PIMS at the moment of dispensing. You are losing 4-7x the share of any non-formulary product. Reps who chase trial orders without confirming formulary inclusion are leaving 60% of their revenue on the floor.

### 3. Script Volume Per Vet Per Month

For pharmaceutical-class products, dispensed units per DVM per month, pulled from PIMS export or distributor sell-through (Patterson VetSource, MWI Vetmate, Covetrus Provet Cloud reporting).

**Benchmark by category:**
- Parasiticides (Bravecto, Simparica Trio, NexGard, Credelio): 25-40 doses/DVM/month
- Atopic dermatitis (Apoquel, Cytopoint, Atopica): 8-15 scripts/DVM/month
- Therapeutic diets (Hill's Prescription Diet, Royal Canin Veterinary, Purina Pro Plan Veterinary): 12-22 bags/DVM/month
- Vaccines (multivalent core, lepto, lyme): tied to wellness visit volume, 18-28/DVM/month
- Livestock therapeutics (Draxxin, Excede, Resflor Gold): 4-9 protocols/account/month

A DVM averaging less than half the category benchmark is either prescribing a competitor or operating a low-acuity practice. Reps should diagnose which before the next call.

### 4. Gross Margin Split (Rx vs OTC vs Equipment vs Diagnostics)

The blended GM% by product class. The mix is what makes or breaks the territory P&L.

**Benchmark:**
- Rx pharmaceuticals: 38-48% GM (higher for novel therapeutics, lower for generic parasiticides)
- OTC and consumables: 18-26% GM
- Capital equipment (anesthesia machines, dental units, in-house chem analyzers from IDEXX or Heska/Antech): 22-30% GM, with 35-50% on service contracts
- Diagnostics (IDEXX SDMA, Antech Accuplex, point-of-care): 28-42% GM
- Nutrition: 14-22% GM (volume play)

A rep whose territory mix is 70% OTC is not bad — they are mis-aligned to the comp plan. The fix is rebalancing toward Rx and diagnostics, which means more detailing minutes on those categories.

### 5. Days Sales Outstanding (DSO)

Time from invoice to cash, blended across independents and corporate accounts.

**Benchmark:** 32-45 days blended. Corporate accounts (Mars, NVA, Thrive) pay on net-45 or net-60 contractually but often hit 50-65 days in practice. Independents pay net-30 but often slip to 38-50. Cash and credit-card accounts (rural large-animal vets, mobile vets) hit DSO of 1-7 days.

If your DSO is above 50 days you have a credit problem, a billing-ops problem, or a corporate-procurement-AP problem — usually all three. Distributors with DSO above 55 are losing margin to working capital costs in any rate environment above 4%.

### 6. Route Density (Calls Per Rep Per Day)

Productive face-to-face account visits per rep per working day.

**Benchmark:**
- Distributor field reps (Patterson, MWI, Covetrus, Henry Schein): 12-18 calls/day in dense urban/suburban territories, 6-10 in rural
- Manufacturer specialty reps (Zoetis dermatology, Boehringer oncology, Elanco production animal): 5-8 calls/day with deeper detail per call
- Companion-animal generalist reps: 8-12 calls/day
- Livestock/production-animal reps: 3-6 calls/day, often with longer drive times and on-farm protocol work

Below benchmark almost always traces to one of: bad territory mapping, too much windshield time, low-quality target list, or rep over-investing in two large accounts. Maptive, Badger Maps, or Salesforce Maps fix the first two; the second two are coaching problems.

### 7. Share of Voice (Detailing Minutes)

The percentage of total detail-call time in a practice that goes to your products versus competitors. Pulled from rep call notes in Salesforce or Veeva, validated against IQVIA-style audit panels where available (less robust in vet than human pharma but tools like Vetsource Insights and Animalytix are improving).

**Benchmark:** Category leaders target 35-45% SoV in their core category at high-decile accounts. New entrants need 20-25% just to be remembered. If your SoV is below 15% in a category where you have a competitive product, you are paying for a rep visit and getting nothing.

### 8. New Product Trial-to-Adoption Velocity (T+90 Reorder Rate)

Of accounts that placed a first trial order on a new SKU, the percentage that placed a second order within 90 days.

**Benchmark:** 55%+ for a clinically differentiated product. 35-45% for a me-too. Below 30% and the launch is broken — either clinical results are not landing, pricing is wrong, or the rep is selling on novelty without supporting protocol adoption. Zoetis hit T+90 reorder rates above 75% on the Librela / Solensia osteoarthritis launches by pairing detail visits with in-clinic CE and patient-tracking apps.

### 9. Rep Retention (Annualized)

Voluntary retention of field reps, measured trailing 12 months.

**Benchmark:** 88%+ for established commercial orgs (Zoetis, Boehringer, Merck, Elanco, Patterson, MWI). 80-85% is the industry median including smaller specialty companies. Below 75% and you have a comp plan, manager, or territory-design problem that is destroying every other KPI on this list — territory disruption costs roughly 0.6-1.1x annual quota in lost revenue and ramp time.

## Real Operators

**Zoetis** — The category leader, roughly $9B in revenue, split between companion animal (Apoquel, Simparica, Librela, Solensia) and livestock (Draxxin, Excede, dairy reproductive). Runs a tiered specialty-rep model with dedicated derm, parasiticide, pain, and diagnostics teams. KPI obsessions: formulary inclusion, T+90 reorder, and corporate MSA depth.

**Boehringer Ingelheim Animal Health** — Number two globally. Strong in vaccines (Vetera, Ingelvac), parasiticides (NexGard, Heartgard), and equine. Acquired Merial in 2017 which reshaped the competitive map. Runs a hybrid generalist + specialty model.

**Merck Animal Health** — Bravecto franchise (parasiticide), HomeAgain (microchip), and a heavy livestock book. Spinning out as a standalone company has sharpened KPI focus on margin per rep and corporate-contract penetration.

**Elanco Animal Health** — Spun out of Eli Lilly in 2019, acquired Bayer Animal Health 2020. Strong in production animal, growing companion-animal book with Credelio, Galliprant, and the AdTab parasiticide line. Has been rebuilding rep retention after the Bayer integration.

**Patterson Veterinary** — One of the big-three distributors, roughly $1B in animal health revenue. Strong in independent companion-animal practices. Runs a high-route-density field model.

**MWI Animal Health (AmerisourceBergen / Cencora)** — The other big distributor, with strong production-animal coverage in addition to companion. Runs more on data and pricing tools than route density alone.

**Covetrus** — Distribution plus practice-management software (AVImark, ImproMed, Pulse) plus home-delivery pharmacy (Vetsource). The integrated stack lets them pitch a different KPI story to practices than pure distributors.

**Henry Schein Animal Health** — Spun off into Covetrus in 2019, the remaining Henry Schein vet business focuses on equipment, technology, and select pharma distribution outside the US.

**Mars Veterinary Health** — The largest corporate consolidator, owns BluePearl Pet Hospital (specialty/ER), VCA (general practice), Banfield Pet Hospital (PetSmart in-store), Antech Diagnostics, and Linnaeus. Procurement runs through a central office in Vernon Hills and Mars HQ in McLean. If you do not have an MSA with Mars, you are not playing in 18-22% of US small-animal revenue.

**IVC Evidensia** — European-headquartered consolidator, growing in North America. More decentralized procurement than Mars but still operates centralized contracts at the country level.

**NVA (National Veterinary Associates)** — Owned by JAB Holding, runs 1,500+ hospitals in North America. Procurement is moderately centralized.

**Thrive Pet Healthcare** — Mid-sized consolidator, more decentralized purchasing, sometimes a faster path to formulary than Mars.

**Hill's Pet Nutrition** (Colgate-Palmolive) and **Royal Canin** (Mars) dominate veterinary therapeutic nutrition with field teams that operate on KPIs closer to consumer-goods than pharma — diet recommendation conversion, in-clinic stocking, and DVM-led home delivery enrollment.

## Failure Modes

**1. Pitching clinical data without margin math.** A rep walks in with three RCTs on Apoquel efficacy and leaves without addressing the dispensing margin difference between Apoquel and a steroid taper. The DVM nods, says "great data," and keeps prescribing prednisone because it pays the practice more per dispense. Fix: every detail call carries a one-page P&L impact sheet with the rep's product alongside the realistic competitor.

**2. Ignoring corporate procurement until renewal week.** A territory rep builds great relationships with three BluePearl ER hospitals, then learns at renewal that Mars central procurement signed an exclusive with a competitor 60 days ago. Corporate contracts need to be worked 6-9 months ahead of renewal at the HQ level, not the hospital level. Manufacturers without a national accounts team get eaten alive here.

**3. Mis-segmenting livestock and companion as one funnel.** A regional VP runs the same comp plan, same call cadence, and same KPI dashboard across feedlot reps and small-animal reps. The feedlot rep with three accounts worth $4M each looks bad on "calls per day" while the companion rep with 80 accounts worth $40k each looks great — until you check margin per call. Always split the comp plan and KPI thresholds at the species line.

**4. Confusing trial orders with adoption.** A new SKU launch dashboard shows 400 trial orders in the first 60 days and the launch is declared a success. T+90 reorder rate is 22%. The 312 practices that did not reorder are now negatively predisposed to your product and your rep. Reorder rate, not first-trial count, is the only launch metric that matters.

## Reporting Cadence

```mermaid
flowchart TD
    A[Daily Stand-up] --> B[Weekly Pipeline]
    B --> C[Monthly QBR Prep]
    C --> D[Quarterly Business Review]
    D --> E[Annual Comp Plan Reset]
    A --> F[Call Reports in Salesforce/Veeva]
    F --> G[Sell-Through from Patterson/MWI/Covetrus]
    G --> B
    B --> H[Formulary Audit via PIMS]
    H --> C
```

**Daily:**
- Rep call reports filed in Salesforce Health Cloud or Veeva Vault CRM within 24 hours
- Route density and call count by rep
- Any same-day escalations from corporate accounts (Mars, NVA, IVC) routed to the national accounts desk

**Weekly:**
- Sell-through from Patterson, MWI, Covetrus, Henry Schein reconciled against territory targets
- Formulary inclusion changes flagged from PIMS data feeds (where available — AVImark and ImproMed via Covetrus, ezyVet via API, Cornerstone via IDEXX)
- T+30 reorder rate on any new SKU launched in the trailing 90 days
- Pipeline review for corporate MSA negotiations in flight

**Monthly:**
- Script volume per DVM per month for the territory, scored against benchmarks
- Gross margin split by product class
- DSO by account type (independent vs corporate vs cash)
- Share of voice estimates from rep call notes
- Rep ride-along scorecards from district managers

**Quarterly:**
- Full QBR with national accounts, regional VPs, finance, marketing, and supply chain
- Rep retention and territory disruption review
- Comp plan attainment percentiles and outlier review
- Forecast roll-up to corporate FP&A
- Strategic account plans for top-decile corporate customers

## 30/60/90 Day Plan

**Days 1-30: Map the territory and the contracts.**
- Pull the full account list and segment by ownership (independent vs corporate-owned vs mixed)
- Identify every corporate MSA touching the territory: status, renewal date, contracted SKUs, current attach rate
- Audit formulary inclusion across the top 25 accounts using PIMS exports
- Ride along with the rep for 2-3 days per region; verify call quality, not just call count
- Lock baseline numbers for every one of the 9 KPIs above

**Days 31-60: Fix the most expensive leak.**
- Of the 9 KPIs, identify the one with the largest gap to benchmark — usually formulary inclusion rate or T+90 reorder
- Build a 4-week sprint to close that specific gap (e.g., 12 targeted lunch-and-learns + clinical liaison support to drive formulary adds)
- Begin corporate MSA renegotiation conversations for any contract renewing in the next 9 months
- Stand up a weekly KPI dashboard in Salesforce or Tableau / Power BI; share with the field

**Days 61-90: Lock the cadence and the comp plan.**
- Confirm reporting cadence is producing decisions, not just slides
- Adjust comp plan SPIFs to drive the specific behaviors moving the lagging KPI (e.g., bonus on T+90 reorder, not just trial order)
- Run a structured T+90 reorder review on every SKU launched in the trailing 6 months — reformulate the rollout for any product below 35% reorder
- Set the annual plan with split targets for companion vs livestock, independent vs corporate, Rx vs OTC vs equipment

## FAQ

**Q1: How much of veterinary sales is now controlled by corporate consolidators?**
A: Roughly 32-40% of US small-animal practice revenue runs through corporate-owned hospitals as of 2027 (Mars Veterinary Health alone is 18-22%, with NVA, IVC Evidensia, Thrive, Pathway, Southern Veterinary Partners, AmeriVet, and Encore making up the remainder). Equine and production-animal segments remain largely independent. Plan your account coverage and national accounts function accordingly.

**Q2: What is the right ratio of generalist to specialty reps for a mid-size animal health company?**
A: For a $200M-$800M animal health business, a workable mix is 65-75% generalist field reps and 25-35% specialty (derm, pain, oncology, parasitology, livestock production). Below $200M you usually cannot afford true specialty coverage and should pair generalists with regional clinical liaisons. Above $1B you start seeing fully matrixed specialty teams like Zoetis runs.

**Q3: Which PIMS systems matter most for formulary tracking?**
A: AVImark, ImproMed Infinity, Cornerstone (IDEXX), ezyVet (IDEXX), and IDEXX Neo cover the majority of US small-animal practices. Pulse Veterinary Technologies and ProVet Cloud are growing in newer/cloud-first practices. For corporate-owned hospitals, the consolidator may run a custom or modified stack — verify directly with their procurement team rather than assuming.

**Q4: How do you actually negotiate with Mars Veterinary Health procurement?**
A: National accounts conversations with Mars run through a central procurement office and typically require 6-9 months from first meeting to signed MSA renewal. Bring category-level economic data (not single-SKU pitches), patient-outcome data from BluePearl/VCA/Antech where you have it, and a clear price/volume curve. Mars procurement is sophisticated and will benchmark you against direct competitors before the meeting.

**Q5: Is the home-delivery pharmacy channel (Vetsource, Chewy PrescribED, PetMeds via Walmart) cannibalizing in-clinic dispensing KPIs?**
A: Yes for OTC parasiticides and chronic-condition Rx; less for acute therapeutics and biologics. By 2027, roughly 25-32% of companion-animal Rx volume flows through home delivery. Smart manufacturers track combined in-clinic + home-delivery script volume per DVM and comp the rep on the total, not just in-clinic dispensing. Practices that lose dispensing margin to home delivery still write the script, so the prescriber relationship is what you protect.

**Q6: What does a strong rep comp plan look like in 2027?**
A: Base salary 55-65% of OTE, variable 35-45%. Variable structure typically: 50-60% on revenue attainment, 20-25% on a strategic KPI mix (formulary inclusion, T+90 reorder, corporate MSA depth), 15-20% on new product launches, 5-10% on training/compliance gates. Accelerators kick in above 100% attainment. Avoid pure top-line revenue comp — it drives trial-order chasing and trashes T+90 reorder rates.

<!--pillar-weave-->
## Related on PULSE

- [What are the key sales KPIs for the Commercial Plastic Surgery Practice industry in 2027?](/knowledge/ik0118)
- [What are the key sales KPIs for the Commercial Chiropractic Practice industry in 2027?](/knowledge/ik0116)
- [What are the key sales KPIs for the Commercial Optometry Practice industry in 2027?](/knowledge/ik0104)
- [What are the key sales KPIs for the Commercial Dental Practice Sales industry in 2027?](/knowledge/ik0103)
- [Top 10 Optometry Practice Revenue KPIs](/knowledge/ik0661)
- [Top 10 Dental Practice Revenue KPIs](/knowledge/ik0658)

## Sources

- AVMA Economic State of the Veterinary Profession Report, 2026 edition
- AAHA (American Animal Hospital Association) State of the Industry, 2026
- Animalytix North American Veterinary Pharmaceutical Sell-Through Data, 2026
- Vetsource Veterinary Industry Tracker quarterly reports, Q1-Q4 2026
- Zoetis Inc. 10-K filing, fiscal year 2026
- Elanco Animal Health 10-K filing, fiscal year 2026
- Boehringer Ingelheim Animal Health annual report, 2026
- Merck Animal Health investor presentations, 2026
- Cencora (AmerisourceBergen) MWI Animal Health segment disclosures, fiscal year 2026
- Patterson Companies Inc. 10-K filing, fiscal year 2026
- Covetrus annual report and operating reviews, 2026
- IDEXX Laboratories Veterinary Software and Diagnostics segment disclosures, 2026
- Mars Veterinary Health public statements and BluePearl/VCA/Banfield/Antech operating data, 2026
- Brakke Consulting Animal Health Industry Reports, 2026 annual edition

Was this helpful?

Deep dive · related in the library

pulse-aquariums · aquariumTop 10 Canister Filters 2027 pulse-aquariums · aquariumTop 10 Hang-On-Back Aquarium Filters 2027 pulse-aquariums · aquariumTop 10 Aquarium Filters 2027 pulse-industry-kpis · industry-kpisThe Best KPIs for Self-Storage Facilities in 2027 pulse-industry-kpis · industry-kpisWhat are the most important KPIs every dermatology practice should track in 2027?pulse-industry-kpis · industry-kpisWhat are the most important KPIs every escape room should track in 2027?pulse-industry-kpis · industry-kpisWhat are the most important KPIs every laundromat should track in 2027?pulse-industry-kpis · industry-kpisWhat are the most important KPIs every dog boarding and daycare business should track in 2027?pulse-industry-kpis · industry-kpisWhat are the most important KPIs every campground should track in 2027?pulse-industry-kpis · industry-kpisWhat are the most important KPIs every winery should track in 2027?

What are the key sales KPIs for the Commercial Veterinary Practice Sales industry in 2027?

Why Commercial Veterinary Practice Sales Sells Differently

The 9 KPIs, In Depth

1. Corporate Contract Attach Rate

2. Formulary Inclusion Rate

3. Script Volume Per Vet Per Month

4. Gross Margin Split (Rx vs OTC vs Equipment vs Diagnostics)

5. Days Sales Outstanding (DSO)

6. Route Density (Calls Per Rep Per Day)

7. Share of Voice (Detailing Minutes)

8. New Product Trial-to-Adoption Velocity (T+90 Reorder Rate)

9. Rep Retention (Annualized)

Real Operators

Failure Modes

Reporting Cadence

30/60/90 Day Plan

FAQ

Related on PULSE

Sources

What does the score mean?